Sulfonylurea is an oral hypoglycemic drug for the treatment of diabetes. It lowers blood sugar levels by stimulating pancreatic β cells to secrete insulin, restores the peak of first-phase insulin secretion in response to glucose and increases first-phase insulin secretion, increases insulin secretion response induced by meals or stimulated by glucose; partially inhibits platelet adhesion and aggregation, reduces platelet activity markers (p-thromboglobulin, thromboxane B2), and produces fibrinolytic activity on the vascular endothelium (increases tPA activity), reducing the process of microthrombosis formation.

A new generation of macrolide antibiotics, it mainly acts on Gram-positive bacteria, anaerobic bacteria, Chlamydia and Mycoplasma, etc. Its in vitro antibacterial effect is similar to that of erythromycin, and its in vivo antibacterial effect is 1 to 4 times stronger than that of erythromycin.

Dilate coronary arteries, increase coronary blood flow, and improve myocardial hypoxia; improve acute cardiovascular and cerebrovascular symptoms and ischemic changes in the electrocardiogram; inhibit platelet aggregation, reduce blood viscosity, and lower blood lipids.

Inhibit platelet aggregation, inhibit platelet release reaction, reduce blood viscosity, and improve myocardial hypoxia.

Compound Danshen Tablets have the effects of dilating coronary arteries, increasing coronary blood flow, slowing heart rate, and improving myocardial hypoxia; it can improve acute cardiovascular and cerebrovascular symptoms and ischemic changes in the electrocardiogram; it can inhibit platelet aggregation, inhibit platelet release reaction, reduce blood viscosity, and lower blood lipids.